Treatment options in first-line metastatic kidney cancer
Over the past 10 years or so, the use of [...]
Quality of life on lenvatinib plus pembrolizumab combination
In this study, the health-related quality of life (HRQoL) of [...]
Sunitinib as a second-line treatment for advanced kidney cancer after combination immunotherapy
The results from a recent phase 2 trial looked at [...]
Risks and benefits of adjuvant therapy for kidney cancer
Treatment of people with intermediate to high risk renal cell [...]
ESMO 2021: TKI treatment breaks for advanced/metastatic kidney cancer – the STAR study
There is increasing interest in using treatment breaks to reduce [...]
Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer
There is very little information on the effectiveness of sunitinib [...]
Biological markers of response for kidney cancer
To date, a reliable biomarker is yet to be discovered [...]
Clinical outcomes of first-line sunitinib followed by immunotherapy
A recent study published in Clinical Genitourinary Cancer has found [...]
Neutrophil-lymphocyte ratio as a prognostic biomarker in high-risk locally advanced kidney cancer
An analysis of the data collected during the S-TRAC study, [...]
Sunitinib re-challenge in patients with metastatic kidney cancer
A study published in Clinical Genitourinary Cancer looks at the [...]
